2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
784
Lung Neoplasms
346
Ovarian Neoplasms
323
Breast Neoplasms
279
Fallopian Tube Neoplasms
159
Triple Negative Breast Neoplasms
146
Small Cell Lung Carcinoma
146
Neoplasms
137
Squamous Cell Carcinoma of Head and Neck
123
Carcinoma, Ovarian Epithelial
114
Neoplasm Metastasis
86
Head and Neck Neoplasms
80
Endometrial Neoplasms
77
Uterine Cervical Neoplasms
72
Esophageal Neoplasms
72
Adenocarcinoma of Lung
71
Neuroblastoma
55
Central Nervous System Neoplasms
53
Carcinoma
50
Lymphoma, Large B-Cell, Diffuse
49
Recurrence
48
Brain Neoplasms
48
Prostatic Neoplasms
44
Parkinson Disease 4, Autosomal Dominant Lewy Body
44
Urinary Bladder Neoplasms
42
Esophageal Squamous Cell Carcinoma
41
Lymphoma
39
Melanoma
35
Carcinoma, Squamous Cell
33
Stomach Neoplasms
31
Interventions
durvalumab
2
tremelimumab
1
ceralasertib
1
aflutinib
1
Radiotherapy
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Non Small Cell Lung Cancer NSCLC
×
Carboplatin
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA